Forest Labs rolls out MDD drug in US
The efficacy of VIIBRYD was established in two 8-week, placebo-controlled trials in adult patients with MDD. The mechanism of the antidepressant effect of VIIBRYD is thought to be
HAYA Therapeutics has secured fast track designation from the US Food and Drug Administration (FDA) for its investigational therapy, HTX-001, to treat symptomatic non-obstructive hypertrophic cardiomyopathy (nHCM).
BioPontis Alliance’s business model combines translational drug research with its own asset based investment fund. BioPontis Alliance, through research alliances, looks for innovative science that has the potential